MedWatch

The focus of Novo’s partnerships

Partnerships and licensing deals are necessary for Novo Nordisk if the company wants to develop the best possible drugs as fast as possible, says the man who ensures that the many partnerships and licensing agreements run smoothly. Read on to see what the Danish pharmaceutical company is focusing on at the moment.

Foto: Colourbox

“The reason I created the alliance management function about four or five years ago was a recognition that our company primarily developed organically, inventing most of our products in-house. It means we are very much geared for organic growth, which offers many benefits. But it also means that we do not have so much experience in collaborating with others. So I am very pleased that we are now being recognized for focusing on it.”

Lars Fruergaard Jørgensen is Senior VP for Corporate Development and IT at Novo Nordisk, and the recognition he is talking about is a survey from the Boston Consulting Group, placing Novo at the top of the list of preferred global collaboration partners for the biotech industry.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP blåstempler ni nye lægemidler i maj

Den europæiske lægemiddelkomite, CHMP, har på dets møde i maj indstillet ni nye lægemidler til godkendelse samt anbefalet, at seks midler kan tages i brug på nye måder. To midler afvist.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier